Goldman Sachs has a Buy rating and a $33 price target on shares of Pharmaceutical Product Dev. (NASDAQ:
PPDI© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
